AltPep
Dr. Levitt pioneered the field of protein modeling and multiscale computational approaches, for which he was co-recipient of the 2013 Nobel Prize in Chemistry. He serves on the Scientific Advisory Boards of Affymetrix, Amgen, Cocrystal Pharma, Dupont Merck Pharmaceuticals and others.
This person is not in the org chart
This person is not in any offices
AltPep
AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world’s most intractable diseases: amyloid diseases. They are currently focusing on CNS disorders, in particular Alzheimer’s Disease (AD). They target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).